Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Roche acquires Stratos Genomics to further develop DNA based sequencing » 06:09
05/22/20
05/22
06:09
05/22/20
06:09
RHHBY

Roche

$0.00 /

+ (+0.00%)

Roche announced that it…

Roche announced that it has acquired Stratos Genomics, an early-stage sequencing technology company to advance the development of Roche's nanopore sequencer. The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion, Roche said in a statement. "Roche is dedicated to creating innovative diagnostics for the most challenging clinical conditions with techniques that are tailored to individual genetic and disease profiles. These solutions address the demands of research and clinical practice to deliver on the promise of personalised healthcare for patients," said Thomas Schinecker, CEO Roche Diagnostics. "We look forward to further advancing our sequencing technology as we move to the next generation of healthcare and welcome the world-class scientists and employees from Stratos Genomics to Roche." Stratos Genomics will continue operations in Seattle, Washington, U.S. Financial details of the agreement were not disclosed.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Over a week ago
Hot Stocks
Roche: Elecsys Anti-SARS-CoV-2 antibody test live at more than 20 U.S. sites » 16:28
05/19/20
05/19
16:28
05/19/20
16:28
RHHBY

Roche

$0.00 /

+ (+0.00%)

Roche announced its…

Roche announced its Elecsys(R) Anti-SARS-CoV-2 antibody test is live at more than 20 commercial and hospital lab sites throughout the United States, with plans in the next several weeks to increase to more than 200 commercial and hospital lab sites with the ability to perform millions of tests per week. The Elecsys Anti-SARS-CoV-2 antibody test received Emergency Use Authorization from the FDA earlier this month

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Hot Stocks
Roche announces fifth indication for Tecentriq in lung cancer approved by FDA » 15:32
05/18/20
05/18
15:32
05/18/20
15:32
RHHBY

Roche

$0.00 /

+ (+0.00%)

Genentech, a member of…

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Tecentriq as a first-line treatment for adults with metastatic non-small cell lung cancer, or NSCLC, whose tumors have high PD-L1 expression, as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development, said, "Today marks the fifth approval of Tecentriq in lung cancer, as we remain committed to providing an effective and tailored treatment option for every person diagnosed with this disease." In the U.S., Tecentriq has received four approvals across NSCLC, including as a single agent or in combination with targeted therapies and/or chemotherapies. It is also approved in combination with carboplatin and etoposide for the first-line treatment of adults with extensive-stage small cell lung cancer.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Recommendations
Roche price target raised to CHF 395 from CHF 385 at Barclays » 12:59
05/15/20
05/15
12:59
05/15/20
12:59
RHHBY

Roche

$0.00 /

+ (+0.00%)

Barclays analyst Emmanuel…

Barclays analyst Emmanuel Papadakis raised the firm's price target on Roche to CHF 395 from CHF 385 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

On The Fly
Allogene jumps, Compugen plunges following release of cancer meeting abstracts » 12:51
05/14/20
05/14
12:51
05/14/20
12:51
MEIP

MEI Pharma

$2.85 /

+0.02 (+0.71%)

, SGEN

Seattle Genetics

$161.66 /

+3.87 (+2.45%)

, EXEL

Exelixis

$24.93 /

-1.6 (-6.03%)

, MGNX

MacroGenics

$25.33 /

-1.17 (-4.42%)

, CGEN

Compugen

$11.20 /

-2.73 (-19.60%)

, INO

Inovio

$13.46 /

+0.11 (+0.82%)

, ALLO

Allogene Therapeutics

$40.79 /

+9.8 (+31.62%)

, MRK

Merck

$79.39 /

+1.52 (+1.95%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

On Wednesday after market…

Open Full Text

ShowHide Related Items >><<
SGEN Seattle Genetics
$161.66 /

+3.87 (+2.45%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRK Merck
$79.39 /

+1.52 (+1.95%)

MGNX MacroGenics
$25.33 /

-1.17 (-4.42%)

MEIP MEI Pharma
$2.85 /

+0.02 (+0.71%)

INO Inovio
$13.46 /

+0.11 (+0.82%)

EXEL Exelixis
$24.93 /

-1.6 (-6.03%)

CGEN Compugen
$11.20 /

-2.73 (-19.60%)

ALLO Allogene Therapeutics
$40.79 /

+9.8 (+31.62%)

MEIP MEI Pharma
$2.85 /

+0.02 (+0.71%)

04/14/20 JonesTrading
MEI Pharma price target raised to $9 from $6 at JonesTrading
04/14/20 Wells Fargo
MEI Pharma price target raised to $13 from $11 at Wells Fargo
SGEN Seattle Genetics
$161.66 /

+3.87 (+2.45%)

05/01/20
Fly Intel: Top five analyst upgrades
05/01/20 Guggenheim
Guggenheim upgrades Seattle Genetics to Buy on 40% sales growth potential
05/01/20 H.C. Wainwright
Seattle Genetics price target raised to $175 from $150 at H.C. Wainwright
05/01/20 Guggenheim
Seattle Genetics upgraded to Buy from Neutral at Guggenheim
EXEL Exelixis
$24.93 /

-1.6 (-6.03%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
MGNX MacroGenics
$25.33 /

-1.17 (-4.42%)

05/14/20 Wedbush
MacroGenics price target raised to $28 from $16 at Wedbush
05/12/20 Credit Suisse
MacroGenics price target raised to $30 from $13 at Credit Suisse
05/06/20 H.C. Wainwright
MacroGenics price target raised to $22 from $18 at H.C. Wainwright
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
CGEN Compugen
$11.20 /

-2.73 (-19.60%)

05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
05/07/20 SVB Leerink
Compugen initiated with an Outperform at SVB Leerink
INO Inovio
$13.46 /

+0.11 (+0.82%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
ALLO Allogene Therapeutics
$40.79 /

+9.8 (+31.62%)

05/14/20 Oppenheimer
Allogene Therapeutics price target raised to $50 from $44 at Oppenheimer
05/14/20 Jefferies
Jefferies raises price target on 'ASCO winner' Allogene Therapeutics to $45
05/14/20 SunTrust
Allogene Therapeutics downgraded to Hold from Buy at SunTrust
05/14/20 Stifel
Durability remains a key question for Allogene's ALLO-501, says Stifel
MRK Merck
$79.39 /

+1.52 (+1.95%)

04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/23/20 Mizuho
Merck business disruptions have been modest, says Mizuho
03/02/20 William Blair
Merck results revive fears about Seattle Genetics' Adcetris, says William Blair
RHHBY Roche
$0.00 /

+ (+0.00%)

05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
SGEN Seattle Genetics
$161.66 /

+3.87 (+2.45%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRK Merck
$79.39 /

+1.52 (+1.95%)

MGNX MacroGenics
$25.33 /

-1.17 (-4.42%)

MEIP MEI Pharma
$2.85 /

+0.02 (+0.71%)

INO Inovio
$13.46 /

+0.11 (+0.82%)

EXEL Exelixis
$24.93 /

-1.6 (-6.03%)

CGEN Compugen
$11.20 /

-2.73 (-19.60%)

ALLO Allogene Therapeutics
$40.79 /

+9.8 (+31.62%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRK Merck
$79.39 /

+1.52 (+1.95%)

INO Inovio
$13.46 /

+0.11 (+0.82%)

SGEN Seattle Genetics
$161.66 /

+3.87 (+2.45%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRK Merck
$79.39 /

+1.52 (+1.95%)

MGNX MacroGenics
$25.33 /

-1.17 (-4.42%)

MEIP MEI Pharma
$2.85 /

+0.02 (+0.71%)

INO Inovio
$13.46 /

+0.11 (+0.82%)

EXEL Exelixis
$24.93 /

-1.6 (-6.03%)

ALLO Allogene Therapeutics
$40.79 /

+9.8 (+31.62%)

MRK Merck
$79.39 /

+1.52 (+1.95%)

MEIP MEI Pharma
$2.85 /

+0.02 (+0.71%)

INO Inovio
$13.46 /

+0.11 (+0.82%)

EXEL Exelixis
$24.93 /

-1.6 (-6.03%)

Recommendations
Arcus Biosciences price target raised to $40 from $22 at Mizuho » 06:43
05/14/20
05/14
06:43
05/14/20
06:43
RCUS

Arcus Biosciences

$30.98 /

+1.61 (+5.48%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Mizuho analyst Mara…

Mizuho analyst Mara Goldstein raised the firm's price target on Arcus Biosciences (RCUS) to $40 from $22 and keeps a Buy rating on the shares. The analyst sees Roche's (RHHBY) tiragolumab data as validation of the synergistic mechanism of the doublet of anti-TIGIT plus PD-(L)1 inhibition, which Arcus is exploring via AB154. The new price target reflects an added probability of success of 50% for AB154.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$30.98 /

+1.61 (+5.48%)

RCUS Arcus Biosciences
$30.98 /

+1.61 (+5.48%)

05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
04/16/20 Cantor Fitzgerald
Gilead may be entertaining acquisition of Arcus, says Cantor Fitzgerald
RHHBY Roche
$0.00 /

+ (+0.00%)

05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
04/30/20 HSBC
Roche upgraded to Hold from Reduce at HSBC
RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$30.98 /

+1.61 (+5.48%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$30.98 /

+1.61 (+5.48%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$30.98 /

+1.61 (+5.48%)

RCUS Arcus Biosciences
$30.98 /

+1.61 (+5.48%)

Upgrade
Roche upgraded to Outperform from Peer Perform at Wolfe Research » 09:30
05/13/20
05/13
09:30
05/13/20
09:30
RHHBY

Roche

/

+

Wolfe Research analyst…

Wolfe Research analyst Timothy Anderson upgraded Roche to Outperform from Peer Perform with a price target of CHF 410, up from CHF 343. While he is not changing his estimates, he has raised his multiple to reflect his view of the company's pipeline and expectation for upward revisions to the outlook.

ShowHide Related Items >><<
RHHBY Roche
/

+

RHHBY Roche
/

+

05/13/20 Wolfe Research
Roche upgraded to Outperform from Peer Perform at Wolfe Research
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
04/30/20 HSBC
Roche upgraded to Hold from Reduce at HSBC
04/28/20 UBS
Roche price target raised to CHF 380 from CHF 350 at UBS
RHHBY Roche
/

+

RHHBY Roche
/

+

RHHBY Roche
/

+

Upgrade
Roche upgraded to Outperform from Peer Perform at Wolfe Research » 05:48
05/13/20
05/13
05:48
05/13/20
05:48
RHHBY

Roche

$0.00 /

+ (+0.00%)

Wolfe Research analyst…

Wolfe Research analyst Timothy Anderson upgraded Roche to Outperform from Peer Perform with a CHF 410 price target.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
04/30/20 HSBC
Roche upgraded to Hold from Reduce at HSBC
04/28/20 UBS
Roche price target raised to CHF 380 from CHF 350 at UBS
04/28/20 Morgan Stanley
Roche price target raised to CHF 370 from CHF 360 at Morgan Stanley
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Hot Stocks
Roche announces launch of new KAPA Target Enrichment portfolio » 10:03
05/12/20
05/12
10:03
05/12/20
10:03
RHHBY

Roche

$0.00 /

+ (+0.00%)

Roche announced the…

Roche announced the launch of the new KAPA Target Enrichment portfolio, consisting of both exome and custom target enrichment solutions for sequencing. "KAPA HyperExome is a whole exome research panel with significantly improved performance over the existing on-market SeqCap portfolio and other products on the market. In addition to the Target Enrichment portfolio, Roche is also launching the new HyperDesign tool that enables researchers to create custom target enrichment designs that utilize the new KAPA HyperChoice probes. The probes are paired with a streamlined, automatable workflow," the company said.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
04/30/20 HSBC
Roche upgraded to Hold from Reduce at HSBC
04/28/20 UBS
Roche price target raised to CHF 380 from CHF 350 at UBS
04/28/20 Morgan Stanley
Roche price target raised to CHF 370 from CHF 360 at Morgan Stanley
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Conference/Events
Jefferies medtech analysts to hold an analyst/industry conference call » 12:25
05/08/20
05/08
12:25
05/08/20
12:25
ABT

Abbott

$94.20 /

+0.29 (+0.31%)

, BDX

Becton Dickinson

$256.03 /

+0.2 (+0.08%)

, BIO

Bio-Rad

$460.14 /

-3.12 (-0.67%)

, CPHD

Cepheid

$0.00 /

+ (+0.00%)

, DGX

Quest Diagnostics

$111.17 /

+3.8 (+3.54%)

, HOLX

Hologic

$52.51 /

-0.43 (-0.81%)

, LH

LabCorp

$165.44 /

+5.43 (+3.39%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

MedTech Analysts Petrone…

MedTech Analysts Petrone & Denhoy, along with Key Opinion Leader Dr. Babkowski, Laboratory Medical Director at Stamford Hospital, discuss COVID-19 testing and point-of-care settings (companies of interest: ABT BDX BIO CPHD HOLX LH RHHBY) on an Analyst/Industry conference call to be held on May 8 at 1 pm.

ShowHide Related Items >><<
ABT Abbott
$94.20 /

+0.29 (+0.31%)

04/20/20 Barclays
Abbott price target raised to $100 from $92 at Barclays
04/20/20 Barclays
Abbott price target raised to $100 from $92 at Barclays
04/17/20 Raymond James
Abbott price target raised to $102 from $92 at Raymond James
04/17/20 Credit Suisse
Abbott price target raised to $106 from $95 at Credit Suisse
BDX Becton Dickinson
$256.03 /

+0.2 (+0.08%)

04/08/20 Wells Fargo
Becton Dickinson price target lowered to $270 from $279 at Wells Fargo
03/04/20 Citi
Becton Dickinson initiated with a Neutral at Citi
03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
02/07/20
Fly Intel: Top five analyst downgrades
BIO Bio-Rad
$460.14 /

-3.12 (-0.67%)

04/08/20 Jefferies
Bio-Rad COVID-19 antibody test 'could be big,' says Jefferies
03/03/20 Citi
Bio-Rad margin expansion story in early innings, says Citi
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Bio-Rad initiated with an Overweight at Wells Fargo
CPHD Cepheid
$0.00 /

+ (+0.00%)

DGX Quest Diagnostics
$111.17 /

+3.8 (+3.54%)

04/28/20
Fly Intel: Top five analyst upgrades
04/28/20 Morgan Stanley
Morgan Stanley upgrades Quest Diagnostics to Overweight on COVID testing boost
04/28/20 Morgan Stanley
Quest Diagnostics upgraded to Overweight from Equal Weight at Morgan Stanley
04/27/20
Fly Intel: Top five analyst upgrades
HOLX Hologic
$52.51 /

-0.43 (-0.81%)

04/30/20
Fly Intel: Top five analyst upgrades
04/30/20 SVB Leerink
Hologic upgraded to Outperform at SVB Leerink on COVID-19 testing capability
04/30/20 JPMorgan
Hologic price target raised to $55 from $45 at JPMorgan
04/30/20 Needham
Hologic price target raised to $60 from $52 at Needham
LH LabCorp
$165.44 /

+5.43 (+3.39%)

04/30/20 JPMorgan
LabCorp price target raised to $188 from $149 at JPMorgan
04/29/20 KeyBanc
LabCorp downgraded at KeyBanc after sharp recovery in share price
04/29/20 KeyBanc
LabCorp downgraded to Sector Weight from Overweight at KeyBanc
RHHBY Roche
$0.00 /

+ (+0.00%)

05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
04/30/20 HSBC
Roche upgraded to Hold from Reduce at HSBC
04/28/20 UBS
Roche price target raised to CHF 380 from CHF 350 at UBS
04/28/20 Morgan Stanley
Roche price target raised to CHF 370 from CHF 360 at Morgan Stanley

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.